Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level
Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level
复制标题
DOI：
10.1016/j.ygyno.2011.09.034
复制
发表时间：
2012-01-01
影响因子：
4.7
通讯作者：
Bae, Duk-Soo
中科院分区：
文献类型：
--
作者：
Lee, Yoo-Young;Choi, Chel Hun;Bae, Duk-Soo
Objective.据报道，较高水平的循环单核细胞与较高的癌症发病率和死亡率有关。我们研究了治疗前循环单核细胞计数与治疗前鳞状细胞癌相关抗原（SCC-Ag）水平相比对宫颈鳞状细胞癌患者癌症特异性生存的作用。我们回顾性纳入了1996年至2007年在韩国首尔三星医疗中心接受治疗的宫颈鳞状细胞癌患者（FIGO IB至IVA期），这些患者在开始初始治疗前2周内有全血细胞计数和分类细胞计数以及血清SCC-Ag水平。我们研究组的788例患者中位随访时间为53.4个月，5年生存率为87.8%。治疗前循环单核细胞计数的中位数为349/mu l（21-1463），SCC-Ag的中位数浓度为1.6 ng/ml（0.1-362.0）。在多变量分析中，治疗前循环单核细胞计数是局部晚期疾病无进展生存期和总生存期的独立预后因素（P=0.007和P=0.038），但在SCC-Ag的情况下不是总生存期的独立预后因素。单核细胞计数和SCC-Ag联合检测可提高SCC-Ag对局部晚期宫颈鳞癌患者的预后价值。局部晚期宫颈鳞状细胞癌患者治疗前较高的循环单核细胞计数与不良预后独立相关。治疗前循环单核细胞计数可被认为是SCC-Ag的一种特异性生物标志物。(C)2011 Elsevier Inc. All rights reserved.
Objective. Higher level of circulating monocyte has been reported to be related with higher cancer incidence and mortality. We investigated the role of pre-treatment circulating monocyte count for cancer specific survival in cervical squamous cell carcinoma patients comparing with pre-treatment squamous cell carcinoma-related antigen (SCC-Ag) level.Methods. We retrospectively enrolled patients with squamous cell carcinoma of the cervix (FIGO stage IB to IVA) who had complete blood cell counts with differential cell count and serum SCC-Ag level within 2 weeks before starting initial treatment and were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007.Results. The 788 patients in our study group had a median follow-up of 53.4 months and a five-year survival rate of 87.8%. The median value for pre-treatment circulating monocyte count was 349/mu l (21-1463), and the median concentration of SCC-Ag was 1.6 ng/ml (0.1-362.0). In multivariable analysis, the pre-treatment circulating monocyte count was an independent prognostic factor for progression-free survival and overall survival in locally advanced disease (P=0.007 and P=0.038) but not in case of SCC-Ag for overall survival. The combined index of monocyte count and SCC-Ag level could enhance the prognostic value of SCC-Ag alone in patients with locally advanced cervical squamous cell carcinoma.Conclusions. A higher pre-treatment circulating monocyte count is independently associated with poor prognosis in patients with locally advanced cervical squamous cell carcinoma. The pre-treatment circulating monocyte count may be considered as an adjunctive biomarker with SCC-Ag. (C) 2011 Elsevier Inc. All rights reserved.